SCHEMBL26327869

SCHEMBL26327869

CCCOC(=O)C(C(=O)OCCC)N(c1ccc(Oc2ccccc2)cc1)c1cc(C)cc(C)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.40
HPGD P15428 1/20 0.40
CRHBP P24387 1/20 0.40
RAB9A P51151 1/20 0.40
CRHR2 Q13324 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 3/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
LTA4H P09960 2/20 0.38
ALDH1A1 P00352 1/20 0.38
KMT2A Q03164 1/20 0.38
USP2 O75604 1/20 0.38
TSHR P16473 1/20 0.38
ALOX5 P09917 1/20 0.38
NPY5R Q15761 1/20 0.37
HSD17B1 P14061 1/20 0.37
HSD17B2 P37059 1/20 0.37
PTGS2 P35354 1/20 0.37
TSPO P30536 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26327958 0.91 LTA4H (0.45) NPC1HPGDCRHBPRAB9ACRHR2
SCHEMBL26327814 0.90 LTA4H (0.44) NPC1HPGDCRHBPRAB9ACRHR2
SCHEMBL20564588 0.83 ALOX5 (0.41) SMN1; SMN2LMNAMAPK1HTTKMT2A
SCHEMBL26327860 0.83 MEN1 (0.39) SMN1; SMN2LMNAALDH1A1KMT2ATSHR
SCHEMBL26327800 0.82 LMNA (0.45) SMN1; SMN2LMNAALDH1A1KMT2A
SCHEMBL26327878 0.81 FFAR1 (0.38) NPC1SMN1; SMN2LMNAALDH1A1HSD17B1
SCHEMBL26325985 0.80 LMNA (0.51) HPGDSMN1; SMN2LMNAALDH1A1KMT2A
SCHEMBL26327935 0.79 POLB (0.40) RAB9ALMNAMAPK1HTTALDH1A1
SCHEMBL26327977 0.78 LMNA (0.46) NPC1HPGDRAB9ASMN1; SMN2LMNA
SCHEMBL26327831 0.78 ALDH1A1 (0.41) NPC1HPGDRAB9ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11767291-B2 Preparation of secondary amines with electrophilic N-linchpin reagents WILLIAM MARSH RICE UNIVERSITY (US) 2023-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11767291-B2 Preparation of secondary amines with electrophilic N-linchpin reagents PNMT, NCL, NPM1 NPC1 2535/4885HPGD 3275/4885CRHBP 942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.